Quick Answer
Arbutus Biopharma Corp reported Total Revenue of $14.08 million for fiscal year 2025.
Arbutus Biopharma Corp — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $14.08M +128.2% |
$6.17M -66.0% |
$18.14M -53.5% |
$39.02M +255.1% |
$10.99M +58.9% |
$6.91M +15.0% |
| Net Income | -$33.50M +52.1% |
-$69.92M +4.0% |
-$72.85M -4.9% |
-$69.46M +8.9% |
-$76.25M -19.6% |
-$63.74M +58.5% |
| Diluted EPS | -$0.17 +55.3% |
-$0.38 +13.6% |
-$0.44 +4.3% |
-$0.46 +44.6% |
-$0.83 +17.0% |
-$1.00 |
| Total Assets | $94.62M -28.2% |
$131.71M -8.8% |
$144.40M -26.1% |
$195.42M -4.4% |
$204.49M +49.2% |
$137.08M +29.9% |
| Cash and Equivalents | $18.01M -50.4% |
$36.33M +38.2% |
$26.29M -14.6% |
$30.78M -71.8% |
$109.28M +109.1% |
$52.25M +64.3% |
| Stockholders Equity | $76.58M -21.4% |
$97.37M -8.2% |
$106.02M -22.5% |
$136.85M -19.2% |
$169.44M +66.2% |
$101.97M +40.2% |
| R&D Expense | $25.24M -53.3% |
$54.04M -26.7% |
$73.70M -12.7% |
$84.41M +28.9% |
$65.50M +32.8% |
$49.34M -14.3% |
| Operating Income | -$38.16M +50.0% |
-$76.32M +2.3% |
-$78.10M -19.3% |
-$65.46M +11.0% |
-$73.52M -27.2% |
-$57.81M +59.8% |
| Shares Outstanding | 192.53M +1.4% |
189.96M +11.8% |
169.87M +7.9% |
157.46M +8.6% |
144.99M +61.7% |
89.68M +38.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $529.0K | -60.5% | -95.1% |
| Net Income | September 30, 2025 | -$7.74M | +60.7% | -406.9% |
| Diluted EPS | September 30, 2025 | -$0.04 | +60.0% | -500.0% |
| Total Assets | September 30, 2025 | $97.71M | -30.4% | -5.4% |
| Cash and Equivalents | September 30, 2025 | $22.41M | -29.6% | -40.1% |
| Stockholders Equity | September 30, 2025 | $77.40M | -27.6% | -6.7% |
| R&D Expense | September 30, 2025 | $5.78M | -59.5% | +5.1% |
| Operating Income | September 30, 2025 | -$8.66M | +59.6% | -681.9% |
| Shares Outstanding | September 30, 2025 | 191.95M | +1.3% | +0.2% |
- Arbutus Biopharma Corp reported Total Revenue of $14.08 million for fiscal year 2025.
- Arbutus Biopharma Corp showed an increase of +128.2% in Total Revenue compared to the prior fiscal year.
- Arbutus Biopharma Corp reported Net Income of -$33.50 million for fiscal year 2025.
- Arbutus Biopharma Corp showed an increase of +52.1% in Net Income compared to the prior fiscal year.
- Arbutus Biopharma Corp reported Diluted EPS of $0.17 per share (loss) for fiscal year 2025.
- Arbutus Biopharma Corp showed an increase of +55.3% in Diluted EPS compared to the prior fiscal year.
- Arbutus Biopharma Corp reported Total Assets of $94.62 million for fiscal year 2025.
- Arbutus Biopharma Corp showed a decrease of -28.2% in Total Assets compared to the prior fiscal year.
- Arbutus Biopharma Corp reported Cash and Equivalents of $18.01 million for fiscal year 2025.
- Arbutus Biopharma Corp showed a decrease of -50.4% in Cash and Equivalents compared to the prior fiscal year.
- Arbutus Biopharma Corp reported Stockholders Equity of $76.58 million for fiscal year 2025.
- Arbutus Biopharma Corp showed a decrease of -21.4% in Stockholders Equity compared to the prior fiscal year.
- Arbutus Biopharma Corp reported R&D Expense of $25.24 million for fiscal year 2025.
- Arbutus Biopharma Corp showed a decrease of -53.3% in R&D Expense compared to the prior fiscal year.
- Arbutus Biopharma Corp reported Operating Income of -$38.16 million for fiscal year 2025.
- Arbutus Biopharma Corp showed an increase of +50.0% in Operating Income compared to the prior fiscal year.
- Arbutus Biopharma Corp reported Shares Outstanding of 192.53 million shares for fiscal year 2025.
- Arbutus Biopharma Corp showed an increase of +1.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: